advertisement
Abstract #19107 Published in IGR 3-1
Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under difference luminance conditions
McDonald JE II; El-Moatassem Kotb AM; Decker BBJournal of Cataract and Refractive Surgery 2001; 27: 560-564
PURPOSE: To evaluate the effect of brimonidine tartrate ophthalmic solution 0.2% (Alphagan®) on pupil size in normal eyes. Three luminance conditions were used to assess the potential use of brimonidine in postoperative refractive patients who experience night-time vision problems related to large pupil size. METHODS: Pupil size was measured in 16 eyes of 16 participants with the Colvard pupillometer under three luminance conditions. One drop of brimonidine 0.2% was administered to each patient. Pupil size was then measured using the same technique 30 minutes and four and six hours after drop administration. RESULTS: Under scotopic conditions, 100% of the pupils showed significant miosis at 30 minutes (p < 0.05). The effect continued in all eyes for four hours. At six hours, a miotic effect was still present in 81.3%. However, under photopic luminance, there was no significant effect on pupil size in all 16 eyes (p > 0.05). The pupil size in five eyes (31.2%) was not affected at 30 minutes, or at four or six hours. At six hours, 15 eyes (93.8%) had returned to their preinstillation size. CONCLUSIONS: Brimonidine tartrate 0.2% had a significant effect in decreasing pupil size under scotopic conditions. These results indicate that the drug can decrease night-vision difficulties such as halos, star bursts, glare, and monocular diplopia in postoperative refractive patients.
Dr J.E. McDonald II, McDonald Eye Associates, 3318 North Hills Boulevard, Fayetteville, AR 72703-4008, USA. mcdonaldje@mcdonaldeye.com
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
